Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.
about
Screening for prostate cancerScreening for prostate cancerProstate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based AnalysisAssessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialAssessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial.Prostate-cancer mortality at 11 years of follow-up.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.What do the screening trials really tell us and where do we go from here?Serum total and HDL cholesterol and risk of prostate cancerThe implementation of screening for prostate cancer.The current evidence on statin use and prostate cancer prevention: are we there yet?Impact of cause of death adjudication on the results of the European prostate cancer screening trial.Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007.The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study.Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.What explains the differences between centres in the European screening trial? A simulation study.
P2860
Q24201690-B5C14A47-A9A6-4E48-BE1C-BC765470E152Q24245476-37012C51-3908-44A0-8AE0-312D2DE45385Q26781093-561A0178-E4D9-454A-8A1D-700C1B3C7760Q28286011-C5B22B88-A32B-470B-ADA1-7E53F2521F51Q33781171-CD46C596-0DBC-4015-8728-8DF534460FE4Q34261229-38E7175D-5C1D-4E5C-B20F-04CF07C8235DQ34326169-9108D435-25B8-4B27-A18F-414C85AA2AF3Q35234770-FFC16090-D538-4DEC-BECA-A4DF40EF5B92Q36407365-7700B17E-5902-47F6-B879-3F579440B91AQ37777325-B745A1B8-C7D8-4138-B528-7C1EFBA85753Q38800777-216188EB-C1E4-4F7C-826A-F3CFF2D7B4F5Q39180719-C3ED94CC-BFF7-4CBF-A1DE-3EFECC2BD932Q40123788-86009360-901E-41DD-AC9E-F77C411864F0Q44328071-96FA3F7E-8F89-4DF5-A15E-E97A7605A746Q45344726-866F135B-11BC-4D29-B110-54F34A2E7C5FQ46371842-E467F150-8AE4-48F6-AA90-D67CFCDEE5A0Q47358352-750C1572-14ED-4980-A385-C3AF4504F694Q50878494-A2E3E251-DAD0-420E-99B6-47BF65784AF6Q51302170-41FDDC64-F6C7-4BA7-AB58-C6FA322396B8
P2860
Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Contamination by opportunistic ...... of Prostate Cancer Screening.
@en
Contamination by opportunistic ...... of Prostate Cancer Screening.
@nl
type
label
Contamination by opportunistic ...... of Prostate Cancer Screening.
@en
Contamination by opportunistic ...... of Prostate Cancer Screening.
@nl
prefLabel
Contamination by opportunistic ...... of Prostate Cancer Screening.
@en
Contamination by opportunistic ...... of Prostate Cancer Screening.
@nl
P2093
P2860
P1433
P1476
Contamination by opportunistic ...... of Prostate Cancer Screening.
@en
P2093
P2860
P304
P356
10.1111/J.1464-410X.2003.04407.X
P478
92 Suppl 2
P577
2003-12-01T00:00:00Z